Abstract
Acne vulgaris is a common neutrophil-driven inflammatory skin disorder in which Cutibacterium acnes (C. acnes) is known to play a key role. For decades, antibiotics have been widely employed to treat acne vulgaris, inevitably resulting in increased bacterial antibiotic resistance. Phage therapy is a promising strategy to combat the growing challenge of antibiotic-resistant bacteria, utilizing viruses that specifically lyse bacteria. Herein, we explore the feasibility of phage therapy against C. acnes. Eight novel phages, isolated in our laboratory, and commonly used antibiotics eradicate 100% of clinically isolated C. acnes strains. Topical phage therapy in a C. acnes-induced acne-like lesions mouse model affords significantly superior clinical and histological scores. Moreover, the decrease in inflammatory response was reflected by the reduced expression of chemokine CXCL2, neutrophil infiltration, and other inflammatory cytokines when compared with the infected-untreated group. Overall, these findings indicate the potential of phage therapy for acne vulgaris as an additional tool to conventional antibiotics.
| Original language | American English |
|---|---|
| Article number | 1005 |
| Journal | Nature Communications |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| State | Published - Dec 2023 |
Bibliographical note
Funding Information:We would like to thank Dr. Simon Yona for advising with flow cytometry, and supplying the materials for the flow analysis, the Core Research Facility of the Hebrew University, Ein Karem Campus, Dr. Abed Nasereddin and Dr. Idit Shiff for the deep sequencing, and Dr. Eduard Berenshtein for the TEM. We are grateful to Mariana Scherem for helping us prepare our in-vivo experiments. Funding: United States–Israel Binational Science Foundation Grant #2017123 granted to Prof. Ronen Hazan. Israel Science Foundation IPMP Grant #ISF1349/20 granted to Prof. Ronen Hazan. Rosetrees Trust Grant A2232 was granted to Prof. Ronen Hazan. Milgrom Family Support Program granted to Prof. Ronen Hazan. Gishur Fund of Hadassah Medical Center granted to Dr. Vered Molho-Pessach. George and Linda Hiltzick’s donation to Hadassah Medical Center was granted to Dr. Vered Molho-Pessach.
Funding Information:
We would like to thank Dr. Simon Yona for advising with flow cytometry, and supplying the materials for the flow analysis, the Core Research Facility of the Hebrew University, Ein Karem Campus, Dr. Abed Nasereddin and Dr. Idit Shiff for the deep sequencing, and Dr. Eduard Berenshtein for the TEM. We are grateful to Mariana Scherem for helping us prepare our in-vivo experiments. Funding: United States–Israel Binational Science Foundation Grant #2017123 granted to Prof. Ronen Hazan. Israel Science Foundation IPMP Grant #ISF1349/20 granted to Prof. Ronen Hazan. Rosetrees Trust Grant A2232 was granted to Prof. Ronen Hazan. Milgrom Family Support Program granted to Prof. Ronen Hazan. Gishur Fund of Hadassah Medical Center granted to Dr. Vered Molho-Pessach. George and Linda Hiltzick’s donation to Hadassah Medical Center was granted to Dr. Vered Molho-Pessach.
Publisher Copyright:
© 2023, The Author(s).